Analysts Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $18.29

Elanco Animal Health Incorporated (NYSE:ELAN) has been given an average rating of “Moderate Buy” by the seven brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $18.29.

A number of equities research analysts have recently weighed in on ELAN shares. Piper Sandler restated a “neutral” rating and issued a $19.00 price objective (up from $18.00) on shares of Elanco Animal Health in a report on Monday, May 13th. Barclays upped their price objective on Elanco Animal Health from $19.00 to $23.00 and gave the stock an “overweight” rating in a research report on Thursday, May 9th.

Insiders Place Their Bets

In other news, Director William F. Doyle acquired 15,000 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The stock was acquired at an average cost of $16.98 per share, with a total value of $254,700.00. Following the completion of the acquisition, the director now owns 76,330 shares of the company’s stock, valued at $1,296,083.40. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.57% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Primecap Management Co. CA grew its stake in shares of Elanco Animal Health by 2.9% in the 4th quarter. Primecap Management Co. CA now owns 50,600,324 shares of the company’s stock valued at $753,945,000 after purchasing an additional 1,431,665 shares during the last quarter. Vanguard Group Inc. increased its stake in Elanco Animal Health by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock valued at $737,083,000 after buying an additional 467,196 shares during the period. Price T Rowe Associates Inc. MD raised its position in Elanco Animal Health by 4.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock worth $360,425,000 after buying an additional 852,281 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Elanco Animal Health by 33.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 15,095,179 shares of the company’s stock worth $224,920,000 after acquiring an additional 3,816,514 shares during the period. Finally, Ancora Advisors LLC boosted its holdings in shares of Elanco Animal Health by 1.4% in the first quarter. Ancora Advisors LLC now owns 10,641,194 shares of the company’s stock valued at $173,239,000 after acquiring an additional 143,326 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Up 0.7 %

Shares of NYSE ELAN opened at $17.97 on Monday. The stock has a market cap of $8.88 billion, a P/E ratio of -6.78, a PEG ratio of 1.73 and a beta of 1.45. The business’s fifty day simple moving average is $16.39 and its 200-day simple moving average is $15.67. Elanco Animal Health has a 12-month low of $8.52 and a 12-month high of $18.80. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.95.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter last year, the company earned $0.45 EPS. Elanco Animal Health’s revenue for the quarter was down 4.1% compared to the same quarter last year. As a group, equities analysts predict that Elanco Animal Health will post 0.93 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.